Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model
- 58 Downloads
Urokinase-type plasminogen activator (uPA) initiates an extracellular proteolytic cascade with which invasive cells eliminate barriers to movement. We have evaluated the antiinvasive and antimetastatic properties of two recently developed synthetic uPA inhibitors, B428 and B623, in a BALB/c mouse mammary carcinoma model. We used the F3II and M3 tumor cell lines, previously described by our laboratory.In vitro, noncytotoxic concentrations of B428 or B623 inhibited secreted and cell-associated uPA activity produced by tumor cells and blocked uPA-mediated whole tumor cell degradation of fibronectin, allowing deposition of extracellular fibronectin fibrils.In vivo, administration of compounds was not associated with overt toxic effects. Daily i.p. treatment with B428 (20 mg/kg/day) or B623 (7.5 mg/kg/day) for 2 weeks, beginning after tumor take, markedly blocked the invasion of the muscle and adipose layers of the subcutis and dermis in mice bearing highly invasive F3II tumors. However, these compounds neither inhibited tumor-induced angiogenesis nor reduced the incidence of spontaneous lung metastasis. Moreover, B623 enhanced the formation of experimental lung metastasis. Our results suggest that synthetic uPA inhibitors act as potent antiinvasiveness agentsin vivo but may be unable to control progression of the metastatic disease in the present mammary tumor model.
Key wordsbreast cancer fibronectin invasion mouse mammary tumor model protease inhibitors treatment urokinase
Unable to display preview. Download preview PDF.
- 2.Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139–266, 1985Google Scholar
- 7.Møller LB: Structure and function of the urokinase receptor. Blood Coagul Fibrinol 4: 293–303, 1993Google Scholar
- 14.Alonso DF, Farías EF, Puricelli L, Bal de Kier Joffé E:In vitro andin vivo effects of potassium-sparing diuretics in a urokinase-producing murine mammary adenocarcinoma model. Proc Am Assoc Cancer Res 35: 68, 1994 (Abstract)Google Scholar
- 16.Alonso DF, Farías EF, Bal de Kier Joffé E: Urokinase-type plasminogen activator activity released by clonal tumor cell populations isolated during the growth of a murine mammary adenocarcinoma. J Exp Clin Cancer Res 13: 211–216, 1994Google Scholar
- 17.Bal de Kier Joffé E, Puricelli L, Vidal MC, Sacerdote de Lustig E: Characterization of two murine mammary adenocarcinoma tumors with different metastatic ability. J Exp Clin Cancer Res 2: 151–160, 1983Google Scholar
- 37.Sato Y, Okamura K, Morimoto A, Hamanaka R, Hamaguchi K, Shimada T, Ono M, Kohno K, Sakata T, Kuwano M: Indispensable role of tissue-type plasminogen activator in growth factor-dependent tube formation of human microvascular endothelial cellsin vitro. Exp Cell Res 204: 223–229, 1993PubMedGoogle Scholar
- 38.Alonso DF, Bertolesi GE, Farías EF, Eiján AM, Bal de Kier Joffé E, Lauría de Cidre L: Antimetastatic effects associated with anticoagulant properties of heparin and chemically modified heparin species in a mouse mammary tumor model. Oncology Rep 3: 219–222, 1996Google Scholar
- 41.Constantini V, Zacharski LR: The role of fibrin in tumor metastasis. Cancer Metast Rev 11: 283–290, 1992Google Scholar
- 47.Hauert J, Nicoloso G, Schleuning W, Bachmann F, Schapira M: Plasminogen activator in dextran sulfate-activated euglobulin-fractions: a molecular analysis of factor XII- and prekallikrein-dependent fibrinolysis. Blood 4: 994–999, 1989Google Scholar